Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors

Journal of Clinical Gastroenterology

Volumn 27, Issue SUPPL. 1, 1998, Pages

  Dattilo, Maurizio ^a   Figura, Natale ^b  

^a Medical Research Division   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Antimicrobial activity; Chronic gastritis; H. pylori; Peptic ulcer; Proton pump inhibitors

Indexed keywords

AG 1789; AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR; SULFENAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; CHRONIC GASTRITIS; CONFERENCE PAPER; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CHRONIC DISEASE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 0032441928     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199800001-00027     Document Type: Conference Paper

References (55)

1. Warren JR, Marshall BM. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1: 1273-5.
2. Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GNY. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988;94:33-40.
3. Tytgat GNJ, Lee A, Graham DJ, Dixon MF, Rokkas T. The role of infectious agents in peptic ulcer disease. Gastroenterol Int 1993;6:76-89.
4. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
5. McTavish D, Buckley MMT, Heel RC. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991;42:138-70.
6. Barradel LB, Faulds D, McTavish D, Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid related disorders. Drugs 1992; 44:225-50.
7. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-82.
8. Malfertheiner P. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997;41:8-13.
9. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have a selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
10. Figura N, Bugnoli M, Armellini D, Crabtree JE. Activities of omeprazole and lansoprazole against Helicobacter pylori in vitro. Hepatogastroenterology 1994;41:92-3.
11. Suerbaum S, Leying H, Klemm K, Opferkuch W. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991;10:92-3.
12. Mégraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori. Lancet 1991;337:1486.
13. Bugnoli M, Bayeli PF, Rappuoli R, Pennatini C, Figura N, Crabtree JE. Inhibition of Helicobacter pylori urease by omeprazole. Eur J Gastroenterol Hepatol 1993;5:683-5.
14. Fujiyama K, Fujioka T, Kodama R, Nasu M. Effects of E3810, a novel proton pump inhibitor, against Helicobacter pylori [Abstract]. Am J Gastroenterol 1994;89:A345.
15. Nakao M, Tada M, Tsuchimori K, Uekata M. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1995;14:391-9.
16. Figura N, Crabtree JE, Dattilo M. In vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother 1997;39:585-90.
17. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 1989;248:799-805.
18. Sachs G, Shin JM, Besancon M, Prinz C. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993;7(suppl 1):4-12.
19. Bamba H, Kondo Y, Wong RM, Sekine S, Matsuzaki S. Minimum inhibitory concentration of various single agents and the effect of their combinations against Helicobacter pylori, as estimated by a fast and simple in vitro assay method. Am J Gastroenterol 1997;92:659-62.
20. Gotoh A, Kawakami Y, Akahane T, et al. Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. Microbiol Immunol 1997;41:7-12.
21. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990;34: 1637-41.
22. van Zwet AA, Thjis JC, de Graaf B. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother 1995;39:250-2.
23. Midolo PD, Turnidge JD, Lambert JR, Bell JM. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother 1996;40:1531-3.
24. Levi S, Beardshall K, Haddad G, Playford R, Ghosh P, Calam J. Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1989;1:1167-8.
25. Lichtenberger LM, Dial EJ, Romero JJ, Lechago J, Jarboe LA, Wolfe MM. Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. Gastroenterology 1995;108:320-9.
26. Williams C, Preston T, Slater C, Hossack M, McColl KEL. H. pylori uses urea for amino acid synthesis at neutral pH [Abstract]. Gut 1995;36(suppl 1):A9.
27. Murakami M, Saita H, Teramura S, et al. Gastric ammonia has a potent ulcerogenic action on the rat stomach. Gastroenterology 1993;105:1710-5.
28. Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993;37:769-74.
29. Nagata K, Takagi E, Satoh H, Okamura H, Tamura T. Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum. Antimicrob Agents Chemother 1995; 39:2187-92.
30. McGowan CC, Cover TL, Blaser MJ. The proton pump omeprazole inhibits acid survival of Helicobacter pylon by a urease-independent mechanism. Gastroenterology 1994;107: 738-43.
31. Nagata K, Takagi E, Tsuda M, et al. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother 1995;39:567-70.
32. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725-32.
33. Bauerfeind P, Garner R, Dunn BE, Mobley HLT. Synthesis and activity of Helicobacter pylori urease and catalase at low pH. Gut 1997;40:25-30.
34. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992; 267:10570-5.
35. Figura N, Guglielmetti P, Rossolini A, et al. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol 1989;27:225-6.
36. +-ATPase of gastric cells. A target of Helicobacter pylori cytotoxic activity. FEBS Lett 1993;334:158-60.
37. Figura N, Armellini D, Bugnoli M, Bayeli PF, Gennari C, Crabtree JE. Activity of omeprazole on Helicobacter pylori and relation to toxicity of strains. J Clin Pathol 1994;47:440-2.
38. Cover TL, Puryear W, Pérez-Pérez GI, Blazer MJ. Effect of urease on HeLa cell vacuolation induced by Helicobacter pylori cytotoxin. Infect Immun 1991;59:1264-70.
39. Cover TL, Vaughn SG, Cao P, Blaser MJ. Potentiation of Helicobacter pylori toxin activity by nicotine and other weak bases. J Infect Dis 1992;166:1073-8.
40. Mellman I, Fuchs R, Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986;55:663-700.
41. Belli WA, Fryklund J. Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells. Antimicrob Agents Chemother 1995; 39:1717-20.
42. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993; 88:1801-2.
43. Ge Z, Hiratsuka K, Taylor DE. Nucleotide sequence and mutational analysis indicate that two Helicobacter pylori genes encode a P-type ATPase and a cation-binding protein associated with copper transport. Mol Microbiol 1995;15:97-106.
44. Sobala GM, Crabtree JE, Dixon MK, et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991;32:1415-8.
45. Kozol R, McCurdy B, Czanko R. A neutrophil chemotactic factor present in H. pylori but absent in H. mustelae. Dig Dis Sci 1993;38:137-41.
46. Reymunde A, Deren J, Nachamkin I, Oppenheim D, Weinbaum G. Production of chemoattractant by Helicobacter pylori. Dig Dis Sci 1993;38:1697-701.
47. Nielsen H, Birkholz S, Andersen LP, Moran AP. Neutrophil activation by Helicobacter pylori lipopolysaccharides. J Infect Dis 1994;170:135-9.
48. Norgaard A, Andersen LP, Nielsen H. Neutrophil degranulation by Helicobacter pylori proteins. Gut 1995;36:354-7.
49. Sekiguchi M, Nagaya H, Satoh H, Shino A. Localization of a novel proton pump inhibitor, lansoprazole, in the gastric mucosa of the rat: a radioautographic study. Acta Histochem Cytochem 1992;25:405-10.
50. Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishii H. Lansoprazole inhibits oxygen derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol 1995;20(Suppl 2):S93-6.
51. Scaringi L, Cornacchione P, Fettucciari K, et al. Activity inhibition of cytolytic-lymphocyte by omeprazole. Scand J Immunol 1996;44:204-14.
52. El-Omar E, Penman I, Cruikshank G, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 1994;35:1385-8.
53. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
54. Caselli M, Pedriali R, Ruina M, Gaudenzi P, Gallerani L, Alvisi V. Lansoprazole in gastric juice and H. pylori [Abstract]. Gut 1995;30(Suppl 1):A7.
55. Mezey E, Palkovits M. Localization of targets for anti-ulcer drugs in cells of the immune system. Science 1992;258:1662-5.